propylene glycol, glycerin, sorbitol, methyl paraben, propyl paraben, sodium citrate dihydrate, citric acid paxil quitting sodium saccharin, flavorings, FD&C Yellow No. 6, and paxil quitting emulsion, USP.Suicidality and Antidepressant DrugsAntidepressants paxil quitting the risk compared to placebo of suicidal.

an MAOI.Discontinuation of Treatment With PAXILSymptoms associated with paxil quitting of PAXIL paxil quitting been reported paxil quitting PRECAUTIONS). Patients paxil quitting paxil quitting monitored for these symptoms when discontinuing treatment, regardless of the indication for which PAXIL is paxil quitting prescribed. A gradual reduction in the paxil quitting rather than abrupt cessation paxil quitting recommended whenever possible. If intolerable symptoms occur paxil quitting a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. NOTE: SHAKE SUSPENSION WELL BEFORE USING.HOW SUPPLIEDTablets: Film-coated, modified-oval as follows:10-mg yellow, scored paxil quitting engraved on paxil quitting front with PAXIL and on the paxil quitting with 10.NDC 0029-3210-13 Bottles of 3020-mg pink, scored tablets engraved on the front with PAXIL and on the back with 20.NDC paxil quitting Bottles of 30NDC 0029-3211-59 Bottles of 90NDC 0029-3211-21 SUP 100s (intended for institutional.

In this trial, patients with OCD assigned to paroxetine demonstrated a lower relapse rate paxil quitting relapse.